Clinical Trials
7 trialsNCT04308590 2025-09-04
GRADIENT
Corcept Therapeutics
Phase 3 Completed
NCT03697109 2025-07-16
GRACE
Corcept Therapeutics
Phase 3 Completed
NCT03464045 2025-04-20
Empa PASS on Urinary Tract Malignancies
Boehringer Ingelheim
Completed
NCT04373265 2024-02-23
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Corcept Therapeutics
Phase 1 Completed
NCT02804750 2019-10-15
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Corcept Therapeutics
Phase 2 Completed
NCT02608853 2015-11-20
Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADERâ„¢ Trial Participants
Novo Nordisk A/S
Completed
NCT01195259 2013-10-28
Malignancy Meta Analysis for BRL49653
GlaxoSmithKline
Completed